The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.
To view completed FDA-TRACK performance measures and projects view the Archive Index
Number of results: 6
|Item||Program||Office||Strategic Plan||Strategic Goal/Area|
|1||Develop and Implement Revised CDRH Honor Awards Process||CDRH||Office of Management Operations||CDRH Strategic Plan||Strengthen Our Workforce and Workplace|
|2||Develop a CDRH Employee Resource Center||CDRH||Office of Communication, Education and Radiation Programs||CDRH Strategic Plan||Strengthen Our Workforce and Workplace|
|3||Medical Device Single Audit Program (MDSAP)||CDRH||Office of Compliance||CDRH Strategic Plan||Devices are Legally Marketed in the U.S. and Remain Safe, Effective, and of High-Quality|
|4||Improving the Use of Computational Fluid Dynamic (CFD) Techniques to Evaluate Performance and Blood Damage Safety in Medical Devices||CDRH||Office of Science and Engineering Laboratories||CDRH Strategic Plan||Patients in the U.S. have Access to High-Quality, Safe, and Effective Medical Devices of Public Health Importance First in the World|
|5||Unique Device Identification Database (UDID)||CDRH||Office of Surveillance and Biometrics||CDRH Strategic Plan||Fully Implement a Total Product Life Cycle Approach|
|6||Personalized Medicine||CDRH||Office of In Vitro Diagnostics and Radiological Health||CDRH Strategic Plan||Patients in the U.S. have Access to High-Quality, Safe, and Effective Medical Devices of Public Health Importance First in the World|
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.